Thalassemia Market Size, Share & Trends Analysis Report By Therapeutic Class (Iron Chelating Drugs), By Pipeline (Gene Therapy), By Region (U.S., U.K., France, Germany, Italy, Spain, Japan), And Segment Forecasts, 2016 - 2022

Table of Contents

Chapter 1 Executive Summary
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
Chapter 3 Disease Primer and Epidemiology
3.1 Chapter Summary
3.1.1 Disease Primer
3.1.2 Epidemiology by Indications
3.1.3 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, & EU5)
Chapter 4 Global Market Overview
4.1 Chapter Summary
4.1.1 Introduction and market overview
4.1.2 Market by therapeutic class
4.1.3 Market by treatments
4.1.4 Market size and forecast
4.1.5 Market share distribution for seven major markets (U.S., Japan, and EU5)
4.1.6 Market dynamics among leading brands
4.2 Patent Expiry Analysis
4.3 Drivers & Challenges
4.3.1 Drivers
4.3.2 Challenges
4.4 M&A, Deal Landscape (2013 - 2017 YTD)
4.5 Emerging Markets
4.6 Therapeutic Sector SWOT
Chapter 5 Product Pipeline
5.1 Pipeline Landscape
5.1.1 Leading drugs in development (Chart summary)
5.1.2 Key R&D trends (New targets & MoA)
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late-stage pipeline analysis
5.2.2的概要the disruptive drugs/revolutionary treatments
5.3 Global Pipeline Forecast
Chapter 6 Competitive Landscape
6.1 Bluebird Bio
6.1.1 Company Overview
6.1.2 Current Product Portfolio - Major Products
6.1.3 Product Forecast Sales through 2022
6.1.4 Strategic Initiatives
6.1.5 Key Company News flow
6.1.6 Pipeline View
6.1.7 Catalysts & Events Calendar
6.1.8 SWOT Analysis
6.2 Novartis
6.2.1 Company Overview
6.2.2 Current Product Portfolio - Major Products
6.2.3 Product Forecast Sales through 2022
6.2.4 Strategic Initiatives
6.2.5 Key Company News Flow
6.2.6 Pipeline View
6.2.7 Catalysts & Events Calendar
6.2.8 SWOT Analysis
6.3 Kiadis Pharma
6.3.1 Company Overview
6.3.2 Current Product Portfolio - Major Products
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.5 Key Company News Flow
6.3.6 Pipeline View
6.3.7 SWOT Analysis
6.4 Acceleron Pharma / Celgene Corporation
6.4.1 Company Overview
6.4.2 Current Product Portfolio - Major Products
6.4.3 Strategic Initiatives
6.4.4 Key Company News Flow
6.4.5 Pipeline View
6.4.6 Catalysts & Events Calendar
6.4.7 SWOT Analysis
Chapter 7 Market Outlook
7.1 What the Future Holds
7.2 The Winner and Losers
7.3 Emerging Companies/New Technology Platforms
7.4 The Road Ahead

List of Tables

TABLE 1 Current Prevalence Rates and Numbers for Seven Major Markets - 2016
TABLE 2 Global Thalassemia Market Share Distribution (2016 - 2022)
TABLE 3 U.S. Patents for Current Thalassemia Drugs
TABLE 4 R&D Pipeline Overview
TABLE 5 Late Stage Pipeline
TABLE 6 Disruptive Drug: Lentiglobin
TABLE 7 Disruptive Drug: Luspatercept
TABLE 8 Pipeline Forecast
TABLE 9 Sales Forecast through 2022 (in $ Million)
TABLE 10 Bluebird bio. Pipeline View
TABLE 11 Bluebird bio. Events Calendar
TABLE 12 Sales Forecast, 2016 - 2022 (in $ Million)
TABLE 13 Novartis Pipeline View
TABLE 14 Novartis Events Calendar
TABLE 15 Kiadis Pharma Pipeline View
TABLE 16 Acceleron Pharma Pipeline View
TABLE 17 Acceleron Pharma Events Calendar

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Current prevalence rates for 7 major markets - 2016
FIG. 8 Current prevalence numbers for 7 major markets - 2016
图9水珠al thalassemia market forecast (2016 - 2022)
FIG. 10 Global thalassemia market share distribution (2016 - 2022)
FIG. 11 Market share distribution for seven major markets (U.S., Japan, and EU5)
FIG. 12 SWOT analysis (Global thalassemia market)
FIG. 13 Bluebird bio. Pipeline view
FIG. 14 SWOT analysis (Bluebird bio)
FIG. 15 SWOT analysis (Novartis)
FIG. 16 SWOT analysis (Kiadis Pharma)
FIG. 17 Acceleron pharma pipeline view
FIG. 18 SWOT analysis (Acceleron Pharma/Celgene Corporation)